copper(II) aspirinate, cupric acetylsalicylate, cupric aspirinate, cupric aspirin complex
3D model (Jmol)
|Appearance||Bright blue crystalline solid.|
|Melting point||248 to 255 °C (478 to 491 °F; 521 to 528 K) (decomposes)|
|8.67 h (Human)[Ref#2]|
|US health exposure limits (NIOSH):|
|TWA 1 mg/m3 (as Cu)|
|TWA 1 mg/m3 (as Cu)|
IDLH (Immediate danger)
|TWA 100 mg/m3 (as Cu)|
|Zinc aspirinate, Aluminium aspirinate|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Copper aspirinate can be prepared by several methods. In one route of preparation, an excess of acetylsalicylic acid is dissolved in aqueous sodium carbonate. Sodium hydroxide is not suitable for this purpose, because it will hydrolyse acetylsalicylic acid (ASA) into salicylic acid and sodium acetate.
- 2 HC9H7O4 + Na2CO3 → 2 NaC9H7O4 + CO2↑ + H2O
The resulting solution is then filtered to remove any undissolved acetylsalicylic acid and is mixed with a solution containing Cu2+ cations (copper(II) sulfate is suitable), precipitating bright blue crystals of copper aspirinate immediately. The crystals can then be filtered from solution, washed, and dried. An excess of acetylsalicylic acid is used in the first step, because it eliminates the possibility of unreacted carbonate anions precipitating the copper in this step.
- 4 NaC9H7O4 + 2 CuSO4 → C36H28Cu2O16↓ + 2 Na2SO4
Copper aspirinate has been proven effective as a treatment for rheumatoid arthritis. A pharmacokinetic study in healthy human volunteers supports its enhanced efficacy as compared with aspirin  The studies on animal models suggest that copper aspirinate is very promising in treating against thrombotic diseases and it has all the prospects of success in becoming an antithrombotic drug that prevents and treats thrombotic diseases in humans.
- "NIOSH Pocket Guide to Chemical Hazards #0150". National Institute for Occupational Safety and Health (NIOSH).
- "Rheumatoid Arthritis (RA)". Copper Development Association. June 2000.
- MS Iqbal, M Sher, H Pervez & M Saeed (2008). "Pharmacokinetic Study of Copper (II) Acetylsalicylate" Biol. Trace Elem. Res. 124:283–288. doi:10.1007/s12011-008-8146-3
- Weiping Liu,corresponding author1 Huizhou Xiong, Yikun Yang Ling Li, Zhiqiang Shen, and Zhihe Chen (1998). "Potential Application of Copper Aspirinate in Preventing and Treating Thromboembolic Diseases". Met Based Drugs. Hindawi Publishing Corporation. 5 (3): 123–126. doi:10.1155/MBD.1998.123. PMC . PMID 18475833.
- Allan, J R; A Renton; W E Smith; D L Gerrard; J Birnie (1991). "A Study of the Performance of Bis(acetylsalicylate) Copper(II) and the Cobalt(II), Nickel(II) and Copper(II) Complexes of Pyridine-3,4-dicarboxylic Acid as Colouring Materials for Poly(vinyl chloride) and Polystyrene". Eur. Polym. J. 27 (7): 669–672. doi:10.1016/0014-3057(91)90155-H.